Fryderyk Chopin University of Music

Objectives The initiation of reimbursement for intermittently scanned continuous glucose monitoring (isCGM)/ continuous glucose monitoring (CGM) for those 26 and older could greatly benefit people with type 1 diabetes (PwT1D). The aim of the study was to assess changes in quality of life, metabolic control, fear of hypoglycemia and selected psychological parameters after 3 months of implementation of the isCGM/CGM in PwT1D aged 26 and above. Methods The study involved 57 PwT1D from five diabetology centers. To be included in the study, each participant had to be at least 26 years old, have a minimum of two years of diabetes history. Participants completed a set of validated questionnaires including the FSH-II, DDS, PSS10, DTSQs, WHO-5, PAID, DBQ, and a sociodemographic survey. They also downloaded pump/glucometer data and underwent HbA1c measurement at the beginning and again at the end of the study. Results PwT1D reported higher treatment satisfaction measured by DTSQs. Well-being assessment according to WHO-5 was also higher, and the level of diabetes burnout measured by DBQ, fear of hypoglycemia assessed by HFS-II significantly decreased. Diabetic distress measured by means of total score of DDS lowered. Participants scored also lower on PAID upon follow up. The HbA1c level after three months of using the CGM system was significantly lower. Conclusions The use of isCGM/CGM, even during relatively short observation, leads to improved quality of life, reduced fear of hypoglycemia and diabetes burnout, and lower HbA1c levels in PwT1D over the age of 26 who were naïve to this technology.

The article addresses the role of Zygmunt Noskowski as one of the principal reformers of Polish music education at the turn of the 19th and 20th centuries. The aim of the study is to present his pedagogical, organizational, and publishing activities in the context of shaping a modern model of composition education. The research employed the analysis of historical sources, musicological literature, and a comparative analysis of curricula and textbooks. The results indicate that Noskowski developed a coherent didactic system based on a modern understanding of harmony, counterpoint, and form, which exerted a lasting influence on the development of the Polish compositional school. The conclusions confirm his key importance for the professionalization of music education and the formation of the 20th-century creative milieu.

Digital technologies such as telepsychology, mobile health applications, artificial intelligence (AI), and immersive virtual environments are rapidly transforming the delivery of psychological care. Despite these advances, music therapy remains weakly integrated into most digital mental health systems. In many current interventions, including virtual reality therapies and mental health applications, music is typically used as background ambience rather than as an active therapeutic mechanism. This disconnect limits the potential of music-based interventions for emotional regulation and psychological support. Advances in artificial intelligence create new opportunities to address this gap. Through emotion recognition, behavioral data analysis, and generative music algorithms, AI systems can anticipate emotional states and deliver adaptive musical interventions before psychological distress escalates. Such AI-driven proactive music therapy enables music to function as an embedded regulatory component within digital mental health ecosystems rather than as a passive environmental feature. A conceptual framework for integrating proactive music therapy into digital mental health platforms is proposed, highlighting key technological components including emotion sensing, adaptive music intelligence, and digital therapeutic delivery. Ethical considerations and research priorities for AI-enabled music interventions are also outlined. AI-driven proactive music therapy may represent an important direction for scalable and personalized psychological care in the era of digital mental health.

This pilot study examined the applicability of the Montreal Battery of Evaluation of Amusia (MBEA) in a Polish context and evaluated its capability to distinguish music‑perception performance as a function of prior music education. The authors also explored whether age and musical specialization were associated with MBEA outcomes. A total of 262 participants were included: musicians (n = 103) and psychology students (n = 159), varying in degrees of formal music eduction. In the first phase of study, participants with music education scored above the published cut‑off used to screen for amusia, supporting the potential usefulness of the MBEA as a screening tool. In the second phase, even short‑term formal music education was associated with significantly higher performance on most subtests, including melodic and metric‑rhythmic processing. Musical specialization was not related to performance, which may reflect the relatively standardized tonal and rhythmic training provided in Polish music education. Overall, the results suggest that formal music education is associated with higher MBEA performance and underscore the need for further adaptation and normative work on diagnostic tools such as the MBEA in the Polish population.

2609 Background: Novel treatments are needed for patients with advanced/metastatic NSCLC without actionable driver mutations who progress after prior therapies including checkpoint inhibitors (CPI) and platinum-based chemotherapy. AFM24 is a tetravalent, bispecific ICE that binds CD16A on NK cells and macrophages and EGFR on solid tumors, redirecting and enhancing the innate and possibly the adaptive immune response. The EGFR -wildtype ( EGFR -WT) NSCLC expansion cohort of the Phase 1/2a study (NCT05109442) is evaluating the combination of AFM24 and atezolizumab. Methods: AFM24 is given weekly at 480 mg intravenously (IV) in combination with 840 mg atezolizumab IV fortnightly to patients with advanced or metastatic EGFR -WT NSCLC who progressed on ≥1 prior line of therapy, including at least a platinum doublet and a CPI. The primary endpoint is overall response rate (ORR) by RECIST v1.1 by Investigator assessment. Secondary endpoints include safety, pharmacokinetics, and immunogenicity. Treatment is given in 28-day cycles until disease progression, intolerable toxicity, investigator discretion, or patient withdrawal of consent. Results: As of 15 January 2025, 43 patients received AFM24 and atezolizumab for a mean (range) duration of 19.6 (1–78) weeks. Median (range) age is 67 (40–79) years; 72% male; all patients had an ECOG performance status of 0 (14%) or 1 (86%). Median (range) number of prior lines is 2 (1–7). All patients had discontinued their previous CPI treatment due to progressive disease. The combination was well tolerated with no unexpected toxicities; infusion-related reactions, the most common adverse events (AE), were reported in 54% of patients (28 Grade 1–2, 4 Grade 3). Most common ≥G3 treatment-related AEs were ALT/AST elevations in 2 patients, all fully resolved. The 35 response-evaluable patients showed an ORR of 23% (8 responses: 1 complete response, 7 partial responses), tumor shrinkage in 46% (16/35) and a disease control rate (DCR) of 77%. Of the 8 responders, 6 had never achieved an objective response on prior CPIs. Preliminary median progression-free survival (PFS) is 5.5 months (95% CI 2.9–7.4), with 29% of patients still on treatment. Conclusions: AFM24 in combination with atezolizumab shows promising clinical efficacy in patients who failed prior treatment including platinum-based chemotherapy and CPI. Patients showed a tolerable and well-managed safety profile. A considerable DCR of 77%, with some long, sustained responses was observed. Confirmed responses were achieved in patients who had not responded to prior CPI. This combination treatment approach could offer a promising chemotherapy-free alternative to patients who have exhausted the available therapeutic options and could provide a strategy to overcome resistance to prior CPI. Clinical trial information: NCT05109442 .